UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No.           )

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

o Preliminary Proxy Statement

o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o Definitive Proxy Statement

x Definitive Additional Materials

o Soliciting Material Pursuant to §240.14a-12

Moleculin Biotech, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:

o Fee paid previously with preliminary materials.

o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)	Amount Previously Paid:
(2)	Form, Schedule or Registration Statement No.:
(3)	Filing Party:
(4)	Date Filed:
	Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Moleculin Biotech, Inc.

5300 Memorial Drive, Suite 950

Houston, TX 77007

(713) 300-5160

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD ON MAY 12, 2020

MOLECULIN BIOTECH, INC. ANNOUNCES ADJOURNMENT OF 2020 ANNUAL MEETING OF STOCKHOLDERS TO JUNE 15, 2020

Moleculin Biotech, Inc. (the "Company") has adjourned its 2020 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on May 12, 2020, to June 15, 2020 at 1:30 p.m., local time. As previously announced, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic.  The Annual Meeting will be held at the corporate offices at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

Whether or not stockholders plan to attend the Annual Meeting, the Company encourages all stockholders to vote and submit their proxies in advance of the Annual Meeting by one of the methods described in the previously distributed proxy materials. The record date to determine shareholders who are entitled to attend or vote at the meeting has not changed. Please note that the proxy card included with the previously distributed proxy materials will not be updated to reflect the adjournment and may continue to be used to vote shares in connection with the Annual Meeting. If you have already voted, you do not need to vote again.

Announcement of the voting results of the meeting will be deferred until the adjourned meeting.

Important Notice Regarding the Availability of Proxy Materials

for the Annual Shareholder Meeting to be Held on May 12, 2020:

Electronic Copies of the Proxy Statement and our 2019 Annual Report on Form 10-K are available at

https://materials.proxyvote.com/60855D